WebMar 9, 2024 · Susan Galbraith, Executive Vice President, Oncology R&D, AstraZeneca, said: “Patients with resectable non-small cell lung cancer face unacceptably high rates of recurrence, despite treatment with chemotherapy and surgery. WebNov 11, 2024 · Susan Galbraith Executive Vice President Oncology R&D at AstraZeneca Greater Cambridge Area 4K followers 500+ connections Join to view profile AstraZeneca …
AstraZeneca and Scorpion Therapeutics enter agreement to …
WebNov 11, 2024 · Susan Galbraith, head of Oncology Research & Development at AstraZeneca, discusses the opportunities oncologists can’t walk away from, including HER2, … WebSusan Galbraith’s Post Susan Galbraith Executive Vice President Oncology R&D at AstraZeneca 1y Report this post Report Report. Back ... textadept themes
Susan Galbraith on LinkedIn: #aacr23
WebApr 11, 2024 · PURPOSE We have previously developed and externally validated a prognostic model of overall survival (OS) in men with metastatic, castration-resistant prostate … WebFeb 21, 2024 · Susan Galbraith, Executive Vice President, Oncology R&D, AstraZeneca said: “Today’s historic news from DESTINY-Breast04 could reshape how breast cancer is classified and treated. A HER2-directed therapy has never-before shown a benefit in patients with HER2-low metastatic breast cancer. WebJun 28, 2024 · Susan Galbraith has been tapped to lead AstraZeneca’s Oncology Research & Development program from discovery through late-stage development. She takes over the … text adornment crossword